Abstract: The present invention relates to clinical decision support systems. In detail, the present invention relates to a method for determining the initial fibrinogen concentration in a biological sample, to the use of fibrinogen added to a biological sample in at least one predetermined concentration, to a device for determining the initial fibrinogen concentration in a biological sample, to a computer program comprising program code means for causing a computer to carry out at least several steps of the method according to the invention, to a computer readable non-transitory storage medium containing instructions for carrying out at least some steps of the method according to the invention, and to a kit for determining the initial fibrinogen concentration in a biological sample.

Abstract: The present invention relates to device for determining a fibrinogen level in a sample comprising, a first input for obtaining an attenuance signal over time indicative of a fibrin polymerization of said sample, a second input for obtaining a reactant concentration signal over time indicative of a reactant concentration in said sample, wherein the reactant is any substance leading to the cleavage of fibrinogen to fibrin, a simulation unit running a model using the reactant concentration signal as an input to provide a simulated attenuance signal over time, and an evaluation unit configured to infer the fibrinogen level of said sample by comparing the attenuance signal over time with the simulated attenuance signal over time.

Abstract: The present invention relates to device (10) for determining a fibrinogen level (20) in a sample (22) comprising, a first input for obtaining an attenuance signal (24) over time indicative of a fibrin polymerization of said sample (22), a second input for obtaining a reactant concentration signal (28) over time indicative of a reactant concentration in said sample (22), wherein the reactant is any substance leading to the cleavage of fibrinogen to fibrin, a simulation unit (16) running a model (32) using the reactant concentration signal (28) as an input to provide a simulated attenuance signal (34) over time, and an evaluation unit (18) configured to infer the fibrinogen level (20) of said sample (22) by comparing the attenuance signal (24) over time with the simulated attenuance signal (34) over time.

Abstract: The invention relates to a method for predicting a value of a parameter of a system (20). The value of the parameter of the system (20) is predicted by incrementally optimizing a pharmacokinetic and pharmacodynamic model based on values of parameters of the system (20) received over time. This allows for predicting values of the parameters of the system (20) with improved accuracy. In one embodiment the system (20) comprises a coagulation system (21) comprising an anticoagulant. The predicted value of the parameter of the system (20) can be a point in time at which the coagulation system (21) reaches hemostatic balance after a periodic supply of anticoagulant to the coagulation system (21) is discontinued.

Abstract: A method and system for the assessment of the risk of development of disseminated intravascular coagulation (DIC), in patients showing systemic inflammatory response syndrome (SIRS) or sepsis is disclosed. Specifically, the invention provides a method for early DIC assessment and preventive treatment planning, which has the potential for significantly decreasing mortality rate as well as the rate of DIC related sequelae in the SIRS/sepsis patient population and thereby improving quality of life. The risk assessment method is based on features of vital signs and/or biomarker measurements, and provides solutions for assessing the risk of DIC development 24 hours in advance or within 72 hours after ICU admittance.

Abstract: The present invention relates to a method for estimating a value of a parameter of a blood coagulation system in a subject that is periodically supplied with an anticoagulant, wherein the parameter of the coagulation system is a time taken for the coagulation system to reach a state of coagulation after periodic supply of anticoagulant to the subject is discontinued. The value of the parameter of the coagulation system is estimated based on concentration levels of 5 or 6 coagulation proteins derived from the coagulation system at a predetermined point in time relative to a point in time of supply of a last dose of anticoagulant to the coagulation system. In one embodiment the 5 coagulation proteins are coagulation factor VII (F7), coagulation factor IX (F9), Anti-thrombin (AT), coagulation factor X (F10), and coagulation factor VIII (F8). Optionally the 6th coagulation protein is coagulation factor XI (F11).

Abstract: The present invention relates to clinical decision support systems. In detail, the present invention relates to a method for determining the initial fibrinogen concentration in a biological sample, to the use of fibrinogen added to a biological sample in at least one predetermined concentration, to a device for determining the initial fibrinogen concentration in a biological sample, to a computer program comprising program code means for causing a computer to carry out at least several steps of the method according to the invention, to a computer readable non-transitory storage medium containing instructions for carrying out at least some steps of the method according to the invention, and to a kit for determining the initial fibrinogen concentration in a biological sample.

Abstract: The present invention relates to device (10) for determining a fibrinogen level (20) in a sample (22) comprising, a first input for obtaining an attenuance signal (24) over time indicative of a fibrin polymerization of said sample (22), a second input for obtaining a reactant concentration signal (28) over time indicative of a reactant concentration in said sample (22), wherein the reactant is any substance leading to the cleavage of fibrinogen to fibrin, a simulation unit (16) running a model (32) using the reactant concentration signal (28) as an input to provide a simulated attenuance signal (34) over time, and an evaluation unit (18) configured to infer the fibrinogen level (20) of said sample (22) by comparing the attenuance signal (24) over time with the simulated attenuance signal (34) over time.

Abstract: The present invention provides for a simultaneous graphical representation, a risk of bleeding and a risk of thrombosis providing a visualized bridge therapy process. Furthermore, the present invention provides for a computer-based prediction of the haemostatic situation of the examined blood circulation by using a combination of a biochemical model and a pharmacokinetic model for calculation or another mathematical representation of the blood circulation.

Abstract: The present invention relates to clinical decision support systems. In detail, the present invention relates to a method for determining the hemostatic risk of a subject, to the use of a biomarker's threshold for determining the hemostatic risk of a subject, to a device for determining the hemostatic risk of a subject, to a computer program comprising a program code for carrying out the method for determining the hemostatic risk of a subject, and to a computer-readable non-transitory storage medium containing instructions for carrying out the method for determining the hemostatic risk of a subject.

Abstract: The present invention relates to an apparatus and method for clinical decision support to identify patients at high risk of thrombosis based on a combination of clinical risk factors and molecular markers, e.g., protein concentrations. These clinical risk factors and molecular markers are combined in a machine learning based algorithm which returns an output value, relating to an estimated risk of a thrombosis event in the future.

Abstract: The present invention provides for a clinical decision support system which makes use of a numerical model which dynamically describes a blood dilution of a blood circulation. Based on measured coagulation data and maybe other patient information, loss of hemostatic balance is predicted based on calculations of certain protein concentrations. Additionally, a calculation arrangement translates at least some of the calculated values of concentrations of human blood proteins into a risk value which risk value describes a risk of clotting and/or embolism and/or bleeding. A time development of that risk value is displayed to the user.

Abstract: The present invention provides for a simultaneous graphical representation, a risk of bleeding and a risk of thrombosis providing a visualized bridge therapy process. Furthermore, the present invention provides for a computer-based prediction of the haemostatic situation of the examined blood circulation by using a combination of a biochemical model and a pharmacokinetic model for calculation or another mathematical representation of the blood circulation.

Abstract: A method for estimating concentrations or concentration changes of particular biological markers, e.g. proteins, includes performing estimations by providing a mathematical model with data from measurements of other biological markers, e.g. other proteins. Thus, instead of measuring the concentration of particular proteins, this concentration can be estimated using the model. The estimated proteins can be used together with other clinical data in another model which is able to provide information or estimations of a patient's disease, for example.

Abstract: A classification system (100) for classification of bio molecular data is provided. An input of the system receives a plurality of features (102) of a sample to be classified and a plurality of respective error estimates (104). A statistical module (106) associates probability density functions (108) with the features, wherein variances of the probability density functions depend on the error estimates. A replication module (110) produces a plurality of perturbed replicas (112) of the sample, wherein the features are randomly perturbed according to the corresponding respective probability density functions. A classifier (114) classifies the perturbed replicas based on the perturbed features. An analyzer (118) classifies the sample to be classified based on a statistical analysis of the classified replicas (116) to obtain a sample classification (120).

Abstract: A classification system (100) for classification of bio molecular data is provided. An input of the system receives a plurality of features (102) of a sample to be classified and a plurality of respective error estimates (104). A statistical module (106) associates probability density functions (108) with the features, wherein variances of the probability density functions depend on the error estimates. A replication module (110) produces a plurality of perturbed replicas (112) of the sample, wherein the features are randomly perturbed according to the corresponding respective probability density functions. A classifier (114) classifies the perturbed replicas based on the perturbed features. An analyzer (118) classifies the sample to be classified based on a statistical analysis of the classified replicas (116) to obtain a sample classification (120).

Abstract: The invention relates to a method for estimating concentrations or concentration changes of particular biological markers, e.g. proteins. The estimations are performed by providing a mathematical model with data from measurements of other biological markers, e.g. other proteins. Thus, instead of measuring those particular proteins they can be estimated using the model. The estimated proteins can be used together with other clinical data in another model which is able to provide information or estimations of, for example, a patient's disease.

Abstract: A system is provided that may be used for locating and diagnosing lesions in the human body in vivo. In some embodiments, once the exact position of a lesion is found, a biopsy may be taken from the lesion using e.g. ultra sound techniques for guidance of the biopsy needle. Use of the system drastically reduces the negative biopsy samples compared to currently used “blind sampling” techniques. This reduces patient discomfort and minimizes infections as the number of biopsy samples is reduced. A method and computer-readable medium is also provided.

Abstract: A system for imaging of prostate cancer in a prostate in vivo is provided. The system utilizes Diffuse Optical Tomography (DOT) for creating a 3D image for the detection of suspicious prostate tissue. The DOT image may be used to guide the biopsy, thereby reducing the number of false negatives. A method, computer-readable medium and use are also provided.

Abstract: A detection method is described for detecting an analyte, in particular nucleic acids, in a sample using SE(R)RS, without the need for labeling of the analyte. The detection method is based on the displacement of a labeled surrogate target probe from a capture probe by the analyte in the sample. The present invention also provides a corresponding detection system, to a disposable cartridge for use in such a system, and to a combination of surrogate target probe and capture probe.